Citadel Advisors
RLMD icon

Citadel Advisors’s Relmada Therapeutics RLMD Stock Holding History

Citadel Advisors’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.35M Buy
+1,061,665
New +$7.42M ﹤0.01% 4075
2026
Q1 		– Sell
-28,063
Closed -$133K – 14038
2025
Q4 		$136K Buy
+28,063
New +$94K ﹤0.01% 11405
2024
Q4 		– Sell
-52,846
Closed -$129K – 15244
2024
Q3 		$171K Sell
52,846
-31,467
-37% -$102K ﹤0.01% 10381
2024
Q2 		$253K Buy
84,313
+13,769
+20% +$49.8K ﹤0.01% 9471
2024
Q1 		$328K Sell
70,544
-305,114
-81% -$1.47M ﹤0.01% 9265
2023
Q4 		$1.56M Sell
375,658
-56,437
-13% -$167K ﹤0.01% 5823
2023
Q3 		$1.3M Sell
432,095
-155,699
-26% -$462K ﹤0.01% 6047
2023
Q2 		$1.45M Sell
587,794
-82,239
-12% -$227K ﹤0.01% 5743
2023
Q1 		$1.51M Buy
670,033
+401,017
+149% +$1.38M ﹤0.01% 5895
2022
Q4 		$939K Sell
269,016
-661,588
-71% -$5.81M ﹤0.01% 6937
2022
Q3 		$34.5M Sell
930,604
-16,809
-2% -$466K 0.01% 1358
2022
Q2 		$18M Buy
947,413
+7,941
+0.8% +$173K ﹤0.01% 1956
2022
Q1 		$25.4M Buy
939,472
+645,518
+220% +$13.3M 0.01% 1722
2021
Q4 		$6.62M Sell
293,954
-81,898
-22% -$1.82M ﹤0.01% 3811
2021
Q3 		$9.85M Buy
375,852
+12,869
+4% +$344K ﹤0.01% 3109
2021
Q2 		$11.6M Buy
362,983
+352,522
+3,370% +$12.2M ﹤0.01% 2841
2021
Q1 		$368K Buy
10,461
+2,542
+32% +$88.9K ﹤0.01% 10372
2020
Q4 		$254K Buy
+7,919
New +$272K ﹤0.01% 9366
2020
Q2 		– Sell
-320,072
Closed -$10.9M – 10395
2020
Q1 		$10.9M Buy
320,072
+239,906
+299% +$9.67M ﹤0.01% 1763
2019
Q4 		$3.13M Buy
+80,166
New +$2.44M ﹤0.01% 3732

Other funds holding RLMD

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Citadel Advisors's RLMD Position: Q2 2026 in Review

Citadel Advisors opened a new position in Relmada Therapeutics (RLMD) in Q2 2026: 1,061,665 shares worth $7.35M. The stake represents ﹤0.01% of the portfolio and ranks #4075 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in RLMD as recently as Q4 2025.

Citadel Advisors first reported a position in RLMD in Q4 2019 and has held it in 20 quarters since. The position peaked at $34.5M in Q3 2022. 126 funds tracked by Wall St. Rank hold RLMD as of Q2 2026.

  • Citadel Advisors held 1,061,665 shares of Relmada Therapeutics worth $7.35M as of Q2 2026.
  • Relmada Therapeutics was a new Citadel Advisors position in Q2 2026.
  • Relmada Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #4075 holding.
  • Citadel Advisors first reported a position in Relmada Therapeutics in Q4 2019 and has held it in 20 quarters since.
  • Citadel Advisors's Relmada Therapeutics position peaked at $34.5M in Q3 2022.
  • 126 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.